Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
ConditionProstate Cancer
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexMale
Age18+
SponsorSURGE Therapeutics
About this trial
A Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy
Eligibility criteria
Qualifiers
Males aged 18 years or older at time of informed consent.
Have a histologically confirmed diagnosis of prostate cancer, and are scheduled to undergo radical prostatectomy within 28 days of screening.
Grade Group 2-5.
Eastern Cooperative Oncology Group (ECOG) Performance Status ≤2 at Screening.
Disqualifiers
Have an invasive malignancy, other than the disease under study.
Anticipated to require the use of a drain after radical prostatectomy.
Received any other anticancer therapy (e.g., including but not limited to chemotherapy, biologic therapy, immunotherapy, targeted therapy, endocrine therapy, radiation therapy, intravesical therapy ) within 28 days.
History of allergic reactions attributed to compounds of similar chemical or biologic composition as those used in the STM-416p formulation including poloxamer 407 and sodium hyaluronate.
Trial design
Treatments tested in this trial
- STM-416p
Treatment groups
18 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov